The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

He also has untreated sleep apnea. He would like to try one of the GLP-1 drugs to lose some weight, but I am concerned about ...

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication ...

As I wrote in my last note on Structure: The most famous examples of GLP-1 agonist drugs are Novo Nordisk's (NVO) semaglutide - approved to treat Type 2 Diabetes ("T2D") under the brand name ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...